{"type":"trials","record":{"id":42181,"source_id":"clinicaltrials-gov","external_id":"NCT02088151","title":"Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina","brief_summary":"Laser photocoagulation of the retina targeting the outer layers is an established therapy for proliferative retinopathy and macular edema from diabetic microangiopathy or retinal vein occlusion, centrals serous retinopathy, and extrafoveal subretinal neovascular membranes. However, collateral damage occurs and scotomas can result when using conventional lasers with pulse duration of 100ms and more. This is particularly relevant for laser treatments of the macula where the main therapeutic effect results from stimulation of the retinal pigment epithelium cells and photoreceptor damage is thought to be an unnecessary side effect. Recent experimental research with new laser devices using much shorter pulse duration has shown that photoreceptor damage can be greatly reduced and the retinal pigment epithelium selectively targeted, hence the term selective retinal pigment epithelium laser therapy (SRT). Investigators hypothesize that SRT is equally effective as standard laser photocoagulation for macular disease but minimizes local visual field defects. In this study, patients with central serous retinopathy, macular edema from diabetic microangiopathy or branch vein occlusion, and non-exudative age-related macular degeneration will be treated with SRT. Patients will be assessed 1, 3 and 6 months after treatment.","overall_status":"Terminated","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Insel Gruppe AG, University Hospital Bern","enrollment":18,"countries":["Switzerland"],"start_date":"2010-06-01","completion_date":"2022-02-01","last_update_date":"2023-02-09","source_url":"https://clinicaltrials.gov/study/NCT02088151","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"Insel Gruppe AG, University Hospital Bern","interventions":["Selective retinal pigment epithelium laser therapy using the R:GEN Laser System"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Visual Acuity according to ETDRS protocol — 6 months","Retinal thickness measured by optical coherence tomography — 6 months","Leakage of fluorescein in fluorescein angiography — 6 months","Area of absent fundus autofluorescence — 6 months"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Macular Edema","Central Serous Chorioretinopathy","Retinal Vein Occlusion","Age-related Macular Degeneration","Retinal Neovascularization","Selective retinal pigment epithelium laser therapy using the R:GEN Laser System"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02088151","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2010-06-01 to 2022-02-01","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.931Z","intervention":["Selective retinal pigment epithelium laser therapy using the R:GEN Laser System"],"participants":18,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Visual Acuity according to ETDRS protocol — 6 months","Retinal thickness measured by optical coherence tomography — 6 months","Leakage of fluorescein in fluorescein angiography — 6 months","Area of absent fundus autofluorescence — 6 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42181","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}